SCOPUS 정보 검색 플랫폼

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 283-284

New frontiers for brentuximab vedotin for lymphomas

(1) Moskowitz, Alison J a

a MEMORIAL SLOAN KETTERING CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CARBOPLATIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANTIGEN EXPRESSION; CLINICAL TRIAL (TOPIC); FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MYCOSIS FUNGOIDES; NOTE; PRIORITY JOURNAL; RECURRENT DISEASE; COMPLICATION; FEMALE; KIDNEY FAILURE, CHRONIC; LYMPHOPROLIFERATIVE DISORDERS; METABOLISM;

ANTIGENS, CD30; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84923868991 PISSN: 10428194 EISSN: 10292403 Source Type: Journal
DOI: 10.3109/10428194.2014.974050 Document Type: Note

Times cited : (6)

References (6)

1
- 84902317824
- A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results in patients with DLBCL and other B-cell lymphomas
- Abstract 848
- Bartlett NL, Sharman JP, Oki Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Blood 2013; 122(Suppl. 1): Abstract 848
- (2013) Blood , vol.122
- Bartlett, N.L.¹ Sharman, J.P.² Oki, Y.³

2
- 84901457807
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
- Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014; 123: 3095-3100
- (2014) Blood , vol.123 , pp. 3095-3100
- Horwitz, S.M.¹ Advani, R.H.² Bartlett, N.L.³

3
- 84886747837
- B rentuximab vedotin demonstrates signifi cant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression
- Abstract 797
- K rathen M, Sundram U, Bashey S, et al. B rentuximab vedotin demonstrates signifi cant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression. Blood 2012; 120(Suppl. 1): Abstract 797
- (2012) Blood , vol.120
- Krathen, M.¹ Sundram, U.² Bashey, S.³

4
- 84923235039
- C omplete remission of CD30 positive diff use large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin
- H ill B T, Tubbs R R, Smith M R. C omplete remission of CD30 positive diff use large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leuk Lymphoma 2014; 55: XXX-XXX
- (2014) Leuk Lymphoma , vol.55 , pp. XXX-XXX
- Hill, B.T.¹ Tubbs, R.R.² Smith, M.R.³

5
- 84923867027
- Eff ect of renal impairment on the pharmacokinetics of brentuximab vedotin, an antibody-drug conjugate, in patinets with CD30-positive hematologic malignancies
- Tan TH, Grove, LE, Lynch, CM. Eff ect of renal impairment on the pharmacokinetics of brentuximab vedotin, an antibody-drug conjugate, in patinets with CD30-positive hematologic malignancies. Clin Pharmacol Th er 2013; 93: S17
- (2013) Clin Pharmacol Th Er , vol.93 , pp. S17
- Tan, T.H.¹ Grove² Le³ Lynch⁴ Cm⁵

6
- 53249123632
- 4th ed. Lyon: IARC
- Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
- (2008) WHO Classifi Cation of Tumours of Haematopoietic and Lymphoid Tissues
- Swerdlow, S.H.¹ Campo, E.² Harris, N.L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.